RxDoctor Payments Data

Sarah Mutschlecner

Nurse Practitioner · Chiefland, FLNPI 1831121680

Payments from drug & device makers

$995in general payments, 2019–2025

Across 49 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$289
  • Amgen$157
  • AstraZeneca$153
  • Novo Nordisk$152
  • Exact Sciences$81
  • GSK$71
  • plus $93 from 3 others

What the payments were for

  • Food & beverage$995100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$995 in reported general payments places this provider in the 70th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$2,298
Medicare patients
60
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$28,823
OzempicSemaglutide19$21,754
MounjaroTirzepatide16$19,843
RybelsusSemaglutide14$15,560
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,462
SymbicortBudesonide/Formoterol Fumarate23$5,152
VascepaIcosapent Ethyl11$3,302
Ventolin HfaAlbuterol Sulfate16$871
Albuterol Sulfate HfaAlbuterol Sulfate25$790
Omeprazole26$588
Atorvastatin Calcium57$366
Levothyroxine Sodium63$360
Losartan Potassium50$354
Amlodipine Besylate65$337
Lisinopril63$217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$152$37,31333 claims
Boehringer IngelheimJardiance$21$28,82337 claims
Lilly USA, LLCMounjaro$289$19,84316 claims
GSKTrelegy Ellipta$71$7,46212 claims
AstraZenecaSymbicort$153$5,15223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Chiefland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →